Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.
The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.
This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.
Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.
Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.
To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.
India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.
Credit: AI
Cancer recurrence remains one of the biggest challenges in cancer treatment. Dormant tumour cells are capable of surviving treatment and therapy and can reactivate months or even years later.
Now, researchers say that a new generation of experimental drugs designed to target these dormant cancer cells could offer a promising strategy to prevent the disease from recurring.
The findings come as scientists have been increasingly focusing on tumour dormancy, a state in which cancer cells stop actively multiplying but remain hidden in the body. They become resistant to chemotherapy and other conventional cancer treatments.
The research suggests that targeting the biological pathways controlling dormancy may help stop these cells from getting reactivated and forming new tumours or metastases.
According to researchers, dormant cancer cells are one of the key reasons why some patients experience relapse long after completing treatment.
"Dormant tumour cells are a major driver of cancer recurrence and metastasis," the researchers noted, stating that therapies aimed at controlling or eliminating these cells could change how cancer is treated and managed in the future.
Also read: Bone Marrow Transplant: The Quiet Revolution Transforming India's Fight Against Blood Cancers
Unlike traditional cancer treatments that mainly attack rapidly dividing cells, these new experimental drugs target the molecular signals that allow dormant cancer cells to survive and go unnoticed in the body.
Researchers are investigating several approaches, including blocking pathways that trigger dormant cells to become active again, disrupting the cells' survival mechanisms, and making them more vulnerable to conventional cancer therapies.
Some experimental treatments are also being tested alongside immunotherapy to improve the body's ability to detect and destroy these hidden cells on time.
Scientists say this approach could be especially important for cancers known to recur years after treatment, including breast, lung and certain gastrointestinal cancers.
Cancer recurrence can happen when a small number of cells survive surgery, chemotherapy or radiation. These cells may remain inactive for long periods of time before starting to grow again, eventually leading to a relapse or metastatic diseas.
Researchers believe that the environment of the tumour, immune responses, inflammation and changes in cellular structure and metabolism all play a role in determining whether dormant cancer cells remain inactive or become aggressive again.
While the findings encourage advanced pathways for cancer treatments, experts caution that most drugs that target tumour dormancy are still in the experimental or early clinical trial stage.
Rather than only treating visible tumours, future therapies may also focus on preventing hidden cancer cells from ever becoming active again, potentially reducing the risk of relapse years after successful treatment.
More studies are needed to determine whether they can really reduce cancer recurrence and improve long-term survival in patients.
The promising research comes after a new study found that Viagra, best known as a treatment for erectile dysfunction, may also help stop cancer from spreading.
Researchers from the Weizmann Institute of Science in Israel found that sildenafil, the active ingredient in Viagra, may enhance a newly identified cholesterol-regulating mechanism that could be used to curb cancer metastasis.
The study, published in Cancer Research, showed that sildenafil limits cancer cells' ability to use cholesterol, an essential component of cell membranes.
Cholesterol is especially important for cancer cells that break away from the primary tumor, travel through the body, and invade distant organs. When their access to cholesterol is reduced, these cells have greater difficulty forming metastases.
Credit: AI
A common amino acid found in protein-rich foods, which is also available as an dietary supplement, may have surprising potential for strengthening the body's immune response against cancer and viral infections, according to a new study.
Published in the journal Cell, researchers from Rockefeller University found that arginine plays a key role in helping immune cells detect and attack abnormal cells.
Their findings suggest that restoring arginine levels could improve the effectiveness of the body's natural defences and may one day strengthen cancer or antiviral treatments.
"Our work reveals how a lack of arginine interferes with the immune system, and suggests that upping arginine intake could prove beneficial," said Qiushuang Wu, the study's first author and a postdoctoral researcher at Rockefeller University. "Perhaps that means it could be used in combination with other therapies to treat both cancer and viral infections."
The team investigated how low arginine levels affect gene expression in models of colon cancer, influenza and SARS-CoV-2 infection.
They found that arginine deficiency disrupted the production of major histocompatibility complex class I (MHC-I) proteins, molecules that help cells, allowing the immune system to detect and fight virus-infected or cancerous cells in the body.
The researchers discovered that when arginine was low, ribosomes, the cellular machinery responsible for making proteins, stalled while producing MHC-I proteins. As a result, infected or abnormal cells became harder for the immune system to identify.
However, after giving a moderate amount of arginine, roughly equivalent to a couple of over-the-counter tablets, restored the production of these stalled proteins.
Also read: Bone Marrow Transplant: The Quiet Revolution Transforming India's Fight Against Blood Cancers
Many cancers and viral infections are known to alter amino acid levels in the body. The new findings suggest that these changes may weaken immunity in an unexpected way by limiting the production of proteins essential for a stronger immune response.
Senior author Sohail Tavazoie, head of Rockefeller University's Laboratory of Systems Cancer Biology, believes the discovery could become an asset for future clinical research, especially in cancer treatment studies.
"Arginine supplementation could be readily tested in patients receiving immunotherapies or given to high-risk populations exposed to viral pathogens," Tavazoie said. "Considering that arginine is inexpensive and readily available, we hope that therapeutic and preventative studies could be undertaken soon."
Arginine is an essential amino acid, meaning the body usually produces. Additional amounts of of arginine may be needed during illness, injury or periods of physiological distress to the body.
It is naturally found in foods such as meat, poultry, fish, dairy products, nuts, seeds and legumes. It is also sold as a dietary supplement. It also serves as a building block for nitric oxide, a molecule involved in blood flow and immune function.
While the findings are promising, the researchers emphasise that the study does not prove that taking arginine supplements can prevent or treat cancer or viral infections in people.
Reliable human clinical trials are still needed to determine whether the supplementation is safe, effective and beneficial.
Credit: AI
On August 5, 2026, New York's Medical Aid in Dying (MAID) Act comes into effect which will allow eligible patients with a terminal illness to choose to peacefully end their lives. The end-of-life healthcare will enable patients to have access to end-of-life medications that they could self-administer.
The law marks a significant step in end-of-life healthcare, placing New York among the growing number of U.S. states offering medically assisted dying under strict legal safeguards.
The law is intended for adults who are
The end-of-life right is not available for people with chronic illnesses alone, advanced dementia, or individuals who cannot make informed medical decisions.
Health experts emphasize that medical aid in dying is not the same as euthanasia. Under New York's law, the patient, not the physician, must voluntarily take the prescribed medication.
Doctors evaluate eligibility, discuss alternative care options such as hospice and palliative care, and ensure that the request is informed and free from coercion before a prescription can be issued. Multiple medical assessments are required, making the process regulated and full-proof.
Also read: Assisted Dying Bill Passed In UK: What It Means And How It Changes For End-of-Life Care Forever?
Supporters say the legislation gives terminally ill patients greater autonomy during the final stages of life. Many advocacy groups argue that simply having the option can provide psychological comfort, even for patients who ultimately never take the medication.
Experiences from states where similar laws have existed for years suggest that a significant number of eligible patients obtain the prescription but do not use it.
They instead find reassurance in knowing that they have a choice if suffering becomes unbearable.
At the same time, the law continues to spark ethical and legal debate. Disability rights advocates and some religious organizations have voiced concerns about potential risks to vulnerable populations and the broader implications for end-of-life care.
A group of Catholic healthcare providers has already challenged the law in federal court, arguing that certain provisions requiring patient transfers conflict with their religious beliefs.
For healthcare professionals, the implementation of the MAID Act also means preparing new medical protocols, reporting requirements, and giving appropriate training to staff.
The New York State Department of Health has introduced regulations outlining eligibility criteria, documentation, and safeguards to ensure the law is implemented responsibly while protecting both patients and healthcare providers.
Also read: What Are The Dutch Guidelines Of Active Euthanasia And The Countries That Allow It
Recently, a parliamentary committee in Canada recommended that the country's assisted dying laws must continue to exclude people whose sole underlying condition is a mental illness.
When MAID was introduced in 2016 in Canada, it was available only to adults who were terminally ill. The eligibility criteria were strict.
Individuals had to be suffering from a "serious and incurable illness", be in an "advanced state of irreversible decline", experience "intolerable suffering", and have a natural death that was "reasonably foreseeable".
This legal pathway became primarily served people with terminal cancer or other severe illnesses who wanted greater control over the dying process.
However, many Canadians living with severe non-terminal conditions argued that they were excluded from the law. These included people with degenerative diseases, chronic pain, or spinal injuries who experienced significant suffering but were not nearing death. Many requested MAID but were routinely denied.
© 2024 Bennett, Coleman & Company Limited